BG
PCRX icon

Bellevue Group’s Pacira BioSciences PCRX Stock Holding History

Bellevue Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-51,936
Closed -$3.03M – 182
2022
Q2 		$3.03M Buy
51,936
+30,800
+146% +$2.02M 0.04% 119
2022
Q1 		$1.61M Buy
+21,136
New +$1.41M 0.02% 139

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Bellevue Group's PCRX Position: Q3 2022 in Review

Bellevue Group sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 51,936 shares — an estimated $3.03M sold.

Bellevue Group first reported a position in PCRX in Q1 2022 and held it in 2 quarters. The position peaked at $3.03M in Q2 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

  • Bellevue Group reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
  • Bellevue Group sold 51,936 Pacira BioSciences shares in Q3 2022, an estimated $3.03M.
  • Bellevue Group first reported a position in Pacira BioSciences in Q1 2022 and held it in 2 quarters.
  • Bellevue Group's Pacira BioSciences position peaked at $3.03M in Q2 2022.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.